Trial Profile
Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2015
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- 01 Dec 2015 New trial record